ALB and Alzheimer disease: Albumin To prevenT Infection in chronic liveR failurE (ATTIRE) incorporates a phase II single-arm multicentre feasibility trial (n=80) prior to a phase III randomised controlled trial (RCT) (n=866) assessing the impact of treatment on the incidence of nosocomial infections, organ dysfunction and mortality in patients admitted to hospital with AD of liver cirrhosis.